You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Ultrahigh Throughput Microscale Mass Spectrometry for Pharmaceutical Prenylation Enzyme Engineering

    SBC: Fluid Discovery Inc            Topic: 400

    Project Summary Biocatalyst can be key tools in the synthesis of natural product-based pharmaceuticals and as powerful components of the pharmaceutical chemist’s drug modification kit. For example, the aromatic prenyltransferase NphB has utility in the synthesis of common prenylated compounds or derived backbones include cannabinoids, alpha acids, beta acids, phenylpropanoids, naphterpins, and m ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a commercially viable machine learning product to automatically detect rotator cuff muscle pathology

    SBC: SPRINGBOK INC            Topic: NIAMS

    PROJECT SUMMARY Rotator cuff tears are highly problematic for large patient populations, and therefore remain a very challenging clinical problem. Roughly 20% to 50% of those 60 years of age have a known rotator cuff tear and the prevalence only increases with age. While surgical reconstruction of the rotator cuff seeks to improve shoulder function and stability, the degrees of successful surgical ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD

    SBC: Aromha Inc            Topic: NIA

    Project Summary / Abstract Over 5.8 million Americans are currently affected by Alzheimerandapos;s disease (AD) with an economic burden estimated at andgt; $270 billion/year in 2020 that is projected to increase at least four fold over the next several decades. Accurate biomarkers have been developed that demonstrate that AD pathology is present 15 years of more prior to the onset of memory sympto ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Xenon gas treatment to modulate microglia in neurodegenerative diseases

    SBC: General Biophysics LLC            Topic: NIA

    Administrative Supplement Application PA-20-272 Xenon gas treatment to modulate microglia in neurodegenerative diseases (R41AG073059) ABSTRACT ABSTRACT FROM ORIGINAL APPLICATION Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's Disease

    SBC: WELLSIM BIOMEDICAL TECHNOLOGIES INC            Topic: NIA

    PROJECT SUMMARY / ABSTRACT Alzheimerandapos;s disease (AD) is the most widespread neurodegenerative disorder and has caused a major global health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating studies indicate that neuron-derived extra ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    SBC: VELUM INC            Topic: NIA

    Project Summary There is a world-wide “twin epidemic” of obesity and Type 2 Diabetes (T2D), with an urgent need to find effective new drug treatments for inducing weight loss. Stable derivatives of the endogenous glucoregulatory hormone, glucagon-like peptide-1 (GLP1) are in clinical use for the treatment of T2D but are also of great interest as an emerging treatment of obesity. Another closel ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. 'Novel Shc Blockers as potential Alzheimer's Disease Therapeutics

    SBC: BUTO CORPORATION            Topic: NIA

    Abstract. Alzheimer’s disease (AD) affects more than 5M Americans today, and is the most common cause of dementia in adults. While current medications slightly delay symptoms, no medications exist to cure or stop disease progression. A current focus at NIA is to identify novel drug targets, that address resilience to AD; also, there is an increasing perspective at NIA that Multi-target therapy m ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Bounding generalization risk for Deep Neural Networks

    SBC: Euler Scientific            Topic: NGA20A001

    Deep Convolutional Neural Networks (DCNNs) have become ubiquitous in the analysis of large datasets with geometric symmetries. These datasets are common in medicine, science, intelligence, autonomous driving and industry. While analysis based on DCNNs have proven powerful, uncertainty estimation for such analyses has required sophisticated empirical studies. This has negatively impacted the effect ...

    STTR Phase II 2022 Department of DefenseNational Geospatial-Intelligence Agency
  9. Development of a Gectosome Therapy for Cardiovascular Diseases

    SBC: Vesicle Therapeutics Inc.            Topic: NHLBI

    Project Summary Vesicle Therapeutics Inc aims to develop and commercialize a new therapy for homozygous familial hypercholesterolemia (hoFH). A majority of hoFH is caused by mutations in both alleles of the gene encoding the LDL receptor (LDLR). Since the efficacy of both statins and PCSK9 antibody therapies largely depends on functional LDL receptors, patients with hoFH show limited responses to ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Empowering providers to improve care for disadvantaged patients: design and prototype testing of novel user interface for electronic health records

    SBC: ASP.MD            Topic: 102

    PROJECT SUMMARY There is an emerging digital divide in healthcare between those who care for disadvantaged patients and those who care for less vulnerable populations. In the past decade, electronic health record (EHR) adoption and use has increased but unequally. Providers caring for disadvantaged populations are less likely to have and use advanced EHRs with sophisticated clinical decision suppo ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government